Masimo (NASDAQ:MASI) Given Equal Weight Rating at Wells Fargo & Company

Masimo (NASDAQ:MASI)‘s stock had its “equal weight” rating reaffirmed by research analysts at Wells Fargo & Company in a report issued on Wednesday,Benzinga reports. They presently have a $180.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $190.00. Wells Fargo & Company‘s price target points to a potential upside of 2.65% from the stock’s current price.

A number of other analysts have also commented on the stock. Stifel Nicolaus set a $180.00 target price on shares of Masimo in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Zacks Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price on the stock. in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Monday, December 1st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $181.17.

Masimo Trading Up 0.4%

Shares of NASDAQ MASI traded up $0.67 during mid-day trading on Wednesday, hitting $175.36. The company’s stock had a trading volume of 950,444 shares, compared to its average volume of 1,168,064. The stock has a market cap of $9.42 billion, a price-to-earnings ratio of -16.64, a price-to-earnings-growth ratio of 1.32 and a beta of 1.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92. Masimo has a one year low of $125.94 and a one year high of $194.88. The company’s fifty day simple moving average is $137.00 and its 200-day simple moving average is $142.61.

Institutional Investors Weigh In On Masimo

Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in shares of Masimo by 44.5% in the first quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock valued at $7,311,000 after acquiring an additional 13,513 shares in the last quarter. AQR Capital Management LLC raised its stake in Masimo by 136.5% in the 1st quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock worth $1,305,000 after purchasing an additional 4,700 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Masimo by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Masimo during the 1st quarter worth approximately $220,000. Finally, Jones Financial Companies Lllp raised its position in shares of Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after buying an additional 2,040 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Trending Headlines about Masimo

Here are the key news stories impacting Masimo this week:

• Positive Sentiment: Danaher has signed a definitive agreement to buy Masimo for $180 per share in cash, valuing the transaction at roughly $9.9B; Masimo is expected to operate within Danaher’s Diagnostics segment — this provides a near-term valuation anchor for MASI. PR Newswire
• Positive Sentiment: Market reaction: shares surged sharply after the acquisition news as traders priced in the $180 cash offer and the premium to prior levels, driving heavy volume and sizeable intraday gains. InsiderMonkey
• Positive Sentiment: Strategic rationale: Danaher is buying Masimo to strengthen its diagnostics and patient monitoring capabilities; analysts view the deal as a logical fit that could accelerate product distribution and scale. MedTechDive
• Neutral Sentiment: Deal mechanics and timing: the offer is $180/share in cash and the transaction is expected to close in H2 2026, subject to approvals — MASI may continue trading below the offer price until closing to reflect regulatory, financing and timing risk. Reuters
• Neutral Sentiment: Analyst/estimate caution: some market commentary notes that despite the surge, recent earnings estimate trends for Masimo were weak and could limit upside beyond the deal-arbitrage window. Zacks
• Negative Sentiment: Litigation risk: multiple shareholder-law firms have opened investigations into whether Masimo’s board obtained a fair price, and class-action filings or challenges could complicate or delay closing and create legal costs. PR Newswire – Monteverde

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.